Boehringer's Dulcolax in agency review; Roche rolls back hep C drug prices in India;

> Boehringer Ingelheim's Dulcolax brand kicked off a global creative review, with pitches taking place at the end of June. Report

> Roche ($RHHBY) rolled back the prices on its Exxura treatment for hepatitis C in India, cutting the price by 65% for government institution purchasers. Report

> Bayer and Johnson & Johnson ($JNJ) have presentations on their anticoagulant drug Xarelto scheduled at the International Society on Thrombosis and Haemostasis meeting. Report

> Merck Serono won two prestigious Red Dot Awards for the design of its fertility drug-delivery pens. Release

> Rovi signed up to market Orvatez, a cholesterol-fighting drug that combines Merck & Co.'s ($MRK) Zetia (ezetimibe) with the statin drug atorvastatin, in Spain. Report

And Finally... The biosimilar naming debate is heating up as the FDA plans new guidance by the end of the year. Report

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.